Catalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for Izicopan (C5aR Inhibitor) in Chronic Spontaneous Urticaria. The expected timing is based on the latest available company guidance and may change.
03/19/26:- Positive Ph2a CSU activity; full results planned at 2026 meetings; further development under evaluation. 08/06/26:- Prior Phase 2a CSU activity and safety were reiterated.
Verification
Confirm timing and program details against the company announcement or filing.